Plus, Pfizer releases positive data.
How to play Eli Lilly's stock.
And, RH's "challenging housing market."
Plus, 23andMe's potential proposals.
Plus, Dave & Buster's rising profit.
And, Elon Musk's Dogecoin influence.
Plus, Norfolk Southern's CEO probe.
Too "pricey" or a good time to buy?
Plus, UiPath's $500 million buyback.
And, Solana recovers after bad week.
And, Zscaler's conservative outlook.
And, Volkswagen's Germany plant closures.
